Journal Articles on Mesothelioma: 'Serum Marker/Blood Test' Category
July 22nd, 2008. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk
Subjects heavily exposed to asbestos [>60(ff/cm(3))xyears] showed also a higher level of angiogenic factors. A combination of angiogenic biomarkers with a specific mesothelioma-biomarker such as SMRPs could be used for close surveillance of workers with a history of asbestos exposure.
June 28th, 2008. Soluble Mesothelin Related Protein (SMRP) in an Asbestos Exposed Population
Conclusions: This is the first large scale prospective study of SMRP for screening for malignancy in asbestos-exposed individuals. A high false positive rate was observed. SMRP seems unlikely to prove useful in screening for MM.
June 26th, 2008. Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure
The former was positive for adenocarcinoma markers such as CEA, Ber-EP4, PE-10, thyroid transcription factor-1 and Napsin A, and negative for mesothelial markers including calretinin, D2-40, WT-1 and HBME, while the latter was the opposite, resulting in a diagnosis of coalescing malignant mesothelioma and adenocarcinoma. The panel of antibodies used for immunohistochemistry was useful to distinguish the two different components in the one tumor.
June 24th, 2008. Immunophenotyping of serous carcinoma of the female genital tract
D2-40 and cytokeratin 5/6 are expressed in a considerable proportion of serous carcinomas and should be used cautiously in a 'mesothelioma panel' in situations where serous carcinoma is in the differential diagnosis. HER2/neu was exclusively overexpressed in serous carcinomas of endometrial origin.
June 15th, 2008. Prognostic role of osteopontin expression in malignant pleural mesothelioma
0001), and overall survival analysis showed that low osteopontin expression was associated with longer survival; multivariate analysis confirmed the value of osteopontin expression as an independent prognostic factor (P < . 0001).
June 6th, 2008. Uroplakin is not a Reliable Immunohistochemical Marker for Malignant Mesothelioma of the Pleura
Conclusions: At an antibody dilution for which positive and negative control tissues stain appropriately, PMM does not stain for URO. At higher antibody concentrations, PMM exhibits nonspecific cytoplasmic staining. We assert that URO is not a useful immunohistochemical marker for the detection of PMM. Further studies addressing whether URO is overexpressed at the mRNA level in PMM are warranted.
June 4th, 2008. Malignant mesothelioma 2008
Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.
Posted in Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Full Archive, General, Immune-based Therapies, New & Novel, Occupational Asbestos Exposure, Photodynamic Therapy (PDT), Radiation, SV40, Serum Marker/Blood Test, Survival, Treatment, Type of Assessment: | No Comments »
May 6th, 2008. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma. Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
April 16th, 2008. Evaluation of a series of serum mesothelin in patients with pleural malignant mesothelioma
The analysis of SMRP levels in these patients suggests that it may be a useful marker for monitoring the response to treatment. In fact, it was observed that SMRP increases in patients who did not respond to therapy, it tends to remain stable when therapies results into a clinical stabilization, while it decreases after surgical procedure and in case of clinical improvement.
April 16th, 2008. Serum mesothelin dosages in follow-up of previously exposed workers
No significant variation was observed between mesothelin values at baseline and at follow-up (p = 0. 2).
April 9th, 2008. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: Evaluation in comparison with mesothelin
Conclusions: These findings suggest that diagnostic value of MPF for MPM was better than that of MSLN although both markers showed almost equal specificity for MPM.
April 4th, 2008. The diagnostic value of Ki-67 and repp86 in distinguishing between benign and malignant mesothelial proliferations
Conclusions: Used in combination, Ki-67 and repp86 appear to be useful markers in differentiating MM from benign reactive MH.
March 11th, 2008. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus
This result showed that the SMRP detected with MESOMARK kit should be lack of soluble C-terminus and indistinguishable from C-ERC/mesothelin. Further study might be necessary to demonstrate the relationship between SMRP and mesothelin.
March 8th, 2008. Improved identification of malignant cells in serous effusions using a small, robust panel of antibodies on paraffin-embedded cell suspensions
Conclusion: Immunocytochemical staining of standardized cell block reparations of serous fluid cells with a small panel of 4 antibodies significantly improves diagnostic results compared to cytomorphologic evaluation alone.
February 29th, 2008. New diagnostic markers for malignant pleural mesothelioma
Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.
February 26th, 2008. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma
The transplanted mice have revealed the higher concentrations of rat N-ERC/mesothelin in the blood and ascites than C-ERC/mesothelin. We hope these novel ELISA systems are useful in the rat model system to clarify the mechanism of asbestos-induced carcinogenesis and to develop new effective drugs for mesothelioma.
February 19th, 2008. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: A nested case–control study
High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
February 7th, 2008. PTEN expression is a strong predictor of survival in mesothelioma patients
Conclusion: PTEN is an independent prognostic biomarker in mesothelioma patients. The frequent loss of expression of the tumour suppressor gene PTEN suggests involvement of the PI3K-AKT/protein kinase B (PKB) pathway in MPMs, which may be relevant for future mesothelioma treatment.
|
|  |
